The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) was nearly 11% higher. As of press release, it had risen 10.99% to HK$17.98, with a turnover of HK$5.91 million.

According to the news, Zaiding Pharmaceutical announced that Okela (reptinib) has been approved by the National Drug Administration (NMPA) for the treatment of ROS1-positive adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on the TRIDENT-1 key study, an open-label, single-arm phase 1/2 study that evaluated reptinib in first-time TKI patients and ROS1-positive non-small cell lung cancer patients treated with TKI.

According to reports, reptinib was initially developed by Turning Point (now acquired by Bristol-Myers Squibb) and is a ROS1 and NTRK targeted inhibitor. Zaiding Pharmaceutical has the exclusive right to develop and commercialize this product in Greater China.